BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34044952)

  • 1. Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
    Shahdeo D; Kesarwani V; Suhag D; Ahmed J; Alshehri SM; Gandhi S
    Carbohydr Polym; 2021 Aug; 266():118138. PubMed ID: 34044952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase Plasminogen Activator Receptor-Mediated Targeting of a Stable Nanocomplex Coupled with Specific Peptides for Imaging of Cancer.
    Shahdeo D; Chandra AB; Gandhi S
    Anal Chem; 2021 Aug; 93(34):11868-11877. PubMed ID: 34410104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric biocompatible iron oxide nanoparticles labeled with peptides for imaging in ovarian cancer.
    Shahdeo D; Roberts A; Kesarwani V; Horvat M; Chouhan RS; Gandhi S
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35103283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of U11-functionalized gold nanoparticles for selective targeting of urokinase plasminogen activator receptor-positive breast cancer cells.
    Avvakumova S; Galbiati E; Pandolfi L; Mazzucchelli S; Cassani M; Gori A; Longhi R; Prosperi D
    Bioconjug Chem; 2014 Aug; 25(8):1381-6. PubMed ID: 25080049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.
    Hansen L; Larsen EK; Nielsen EH; Iversen F; Liu Z; Thomsen K; Pedersen M; Skrydstrup T; Nielsen NC; Ploug M; Kjems J
    Nanoscale; 2013 Sep; 5(17):8192-201. PubMed ID: 23835641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
    Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
    J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.
    Yang L; Sajja HK; Cao Z; Qian W; Bender L; Marcus AI; Lipowska M; Wood WC; Wang YA
    Theranostics; 2013; 4(1):106-18. PubMed ID: 24396518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
    Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
    Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
    Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
    Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
    EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to "Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics" [Carbohydrate Polymers, 266, (2021) 118138].
    Shahdeo D; Kesarwani V; Suhag D; Ahmed J; Alshehri SM; Gandhi S
    Carbohydr Polym; 2022 May; 284():119239. PubMed ID: 35287884
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
    Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
    Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activatable Fluorescent Probes Targeting Urokinase-Type Plasminogen Activator Receptor on the Cell Membrane.
    Kim TI; Cho S; Jin H; Bae J; Park C; Kim Y
    Chemistry; 2023 Apr; 29(23):e202203739. PubMed ID: 36734188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
    Yang D; Severin GW; Dougherty CA; Lombardi R; Chen D; Van Dort ME; Barnhart TE; Ross BD; Mazar AP; Hong H
    Oncotarget; 2016 Nov; 7(45):73912-73924. PubMed ID: 27729618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
    Liu D; Overbey D; Watkinson L; Giblin MF
    Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy.
    Li D; Liu S; Shan H; Conti P; Li Z
    Theranostics; 2013; 3(7):507-15. PubMed ID: 23843898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
    J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
    Li Y; Lawrence DA; Zhang L
    J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
    Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
    Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.